Search - tctmd.com

Displaying 221 - 240 of 1259

Sort: Relevancy | Date

Presentation TCT 2016

Trial #4 - The Essentials of ... STICH and STICHES - Ten-Year Follow-up

Presenter: Sunil V. Rao, Harvey D. White, Robert A. Guyton

October 31, 2016

Presentation TCT 2016

Controversy 4. Will the Minimalist Strategy Dominate TAVR in the Future: Supportive Clinical and Economic Data

Presenter: Raj Makkar, Lars Sondergaard, Ganesh Manoharan

October 31, 2016

Presentation TCT 2016

The Moral Imperative and Potential Benefits of Data Sharing: Journalist Perspective

Presenter: C. Michael Gibson, A. Michael Lincoff, Eric D. Peterson

October 31, 2016

Presentation TCT 2016

Late (>5 years) Clinical and Echo Outcomes After TAVR II: The Vancouver Experience

Presenter: Raj Makkar, Lars Sondergaard, John G. Webb

October 31, 2016

Presentation TCT 2016

LEADERS FREE: Pros and Cons

Presenter: Sunil V. Rao, Harvey D. White, Donald Cutlip

October 31, 2016

Presentation TCT 2016

Late (>5 years) Clinical and Echo Outcomes After TAVR I: The Rouen Experience

Presenter: Raj Makkar, Lars Sondergaard, Helene Eltchaninoff

October 31, 2016

Presentation TCT 2016

Trial #3 - The Essentials of ... the LEADERS FREE trial

Presenter: Sunil V. Rao, Harvey D. White, Philip M. Urban

October 31, 2016

Presentation TCT 2016

Pragmatic Simple Trials and Big Data: Implications for NIH Funding

Presenter: Deepak L. Bhatt, Roxana Mehran, Michael S. Lauer

October 31, 2016

Presentation TCT 2016

Controversy 3. Surgical Perspectives on Late Bioprosthetic Valve Durability

Presenter: Raj Makkar, Lars Sondergaard, A. Pieter Kappetein

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy!

Presenter: Raj Makkar, Lars Sondergaard

October 31, 2016

Presentation TCT 2016

Pragmatic Simple Trials and Big Data: Advantages and Caveats

Presenter: Deepak L. Bhatt, Roxana Mehran, Robert A. Harrington

October 31, 2016

Presentation TCT 2016

MATRIX Critique: Pros and Cons

Presenter: Sunil V. Rao, Harvey D. White, Frederick Feit

October 31, 2016

Presentation TCT 2016

Flash Debate: Point 4D-CT Leaflet Thickening Is an Imaging Curiosity With No Clinical Relevance!

Presenter: Raj Makkar, Lars Sondergaard, Ganesh Manoharan

October 31, 2016

Presentation TCT 2016

Trial #2 - The Essentials of ... the MATRIX Trial Access Site and Anticoagulation Type (And Infusion Duration) in ACS

Presenter: Sunil V. Rao, Harvey D. White, Salvatore Brugaletta

October 31, 2016

Presentation TCT 2016

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

Presenter: Raj Makkar, Lars Sondergaard

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint Cerebral Protection Is an Unnecessary and Costly Accessory!

Presenter: Raj Makkar, Lars Sondergaard, Haim Danenberg

October 31, 2016

Presentation TCT 2016

Flash Debate: Point Cerebral Protection Is a Must for All Patients!

Presenter: Raj Makkar, Lars Sondergaard, Axel Linke

October 31, 2016

Presentation TCT 2016

ABSORB III Critique: Pros and Cons

Presenter: Sunil V. Rao, Harvey D. White, Ron Waksman

October 31, 2016

Presentation TCT 2016

MDIC and Industry Perspectives: Potential Effects of NEST on Research, Innovation and Patient Outcomes

Presenter: Owen Faris, Mitchell W. Krucoff, Michael R Minogue

October 31, 2016

Presentation TCT 2016

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

Presenter: Raj Makkar, Lars Sondergaard, Samir R. Kapadia

October 31, 2016

Advertisement

Trial #4 - The Essentials of ... STICH and STICHES - Ten-Year Follow-up

Controversy 4. Will the Minimalist Strategy Dominate TAVR in the Future: Supportive Clinical and Economic Data

The Moral Imperative and Potential Benefits of Data Sharing: Journalist Perspective

Late (>5 years) Clinical and Echo Outcomes After TAVR II: The Vancouver Experience

LEADERS FREE: Pros and Cons

Late (>5 years) Clinical and Echo Outcomes After TAVR I: The Rouen Experience

Trial #3 - The Essentials of ... the LEADERS FREE trial

Pragmatic Simple Trials and Big Data: Implications for NIH Funding

Controversy 3. Surgical Perspectives on Late Bioprosthetic Valve Durability

Flash Debate: Counterpoint 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy!

Pragmatic Simple Trials and Big Data: Advantages and Caveats

MATRIX Critique: Pros and Cons

Flash Debate: Point 4D-CT Leaflet Thickening Is an Imaging Curiosity With No Clinical Relevance!

Trial #2 - The Essentials of ... the MATRIX Trial Access Site and Anticoagulation Type (And Infusion Duration) in ACS

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

Flash Debate: Counterpoint Cerebral Protection Is an Unnecessary and Costly Accessory!

Flash Debate: Point Cerebral Protection Is a Must for All Patients!

ABSORB III Critique: Pros and Cons

MDIC and Industry Perspectives: Potential Effects of NEST on Research, Innovation and Patient Outcomes

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content